To ensure timely access to affordable, safe and effective, high quality biosimilar treatment options, streamlined development must become the default regulatory expectation
Given the heterogeneity in study design, populations, intervention duration, and clinical endpoints, findings were interpreted with careful consideration of variability across the evidence base
It contains Semaglutide as base, an FDA-approved Glucagon-Like Peptide-1 (GLP-1) receptor agonist
If the safety and modest efficacy data from the published trials translate to our patient population, it would give us a tool that acts directly on fat cell metabolism rather than appetite, with a side effect profile that appears extremely well-tolerated
PlexusDx supports a precision-wellness approach: understanding your hormonal status, metabolic biomarkers, and genetic predispositions helps you and your provider evaluate whether GLP-1 treatment aligns with your clinical picture
Coverage for weight-loss medications like Wegovy can vary widely